drugset / Trial / NCT01400828

Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis

NCT01400828

Phase 3 Completed 239 enrolled Yuhan Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

Timeline

Start
2011-06
Primary completion
2013-06
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bilastine Small molecule 20 mg Oral
Comparator Desloratadine Small molecule 5 mg Oral